European Parliament Resolution on Access to (and value of) Medicines

Dear All:

The attached EU Parliament resolution on Access to Medicines was released today. Broadly, it calls for greater transparency in price setting for medicines and for harmonization of HTA processes. Along the way, AMR gets a couple of specific mentions as does the Adaptive Pathway concept that provides some of the logic behind registering antibiotics with relatively smaller programs.

I encourage everyone to take a few minutes to carefully page through it as reading the text directly gives you an excellent sense of the ebb & flow of the debate. You can really feel the philosophical tension between “We want to support industry as innovative pharmaceuticals have value” and “There’s only so much we can afford and these medicines really save lives.”

Note in particular the language calling for compulsory relative effectiveness (RE) estimates. This is a highly problematic concept for many reasons. Although we can (and should) routinely show comparable activity via non-inferiority studies, RE entails to my ear the implicit goal of clinical superiority. This is very challenging (and arguably not desirable) for new anti-infectives as discussed in slides 7-10 of the deck I used at last week’s FDA meeting on animal models in support of narrow-spectrum agents.

An extended written discussion of the tension between superiority and non-inferiority for anti-infectives will come in a paper that we now have in press at Clinical Infectious Diseases. I’m expecting this paper to become an online preprint very soon and will forward that link when it is released.

That said, it will still be necessary for new antibiotics to show their value. The most obvious way is through true novelty. Inventing a new class of fire extinguisher (metaphorically) is the most obvious such path. But, truly novel mechanisms/classes have always been rare birds and we must also find ways to show the value of products that are more incremental in terms of their advance. There’s lots of debate about this at present and I remain hopeful that we’ll find a path.

Best wishes, –jr

 John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx


NIAID BAA – Biodefense focus / Fireside Chat on diagnostics and more

Dear All, We are swimming in Broad Agency Announcements aka BAAs! As a refresher, I recently shared a BAA from the CDC and one from BARDA — now we have another one from NIAID! There’s a strong biodefense angle here with lots of scope. Key details of each opportunity are as follows and I highly recommend you check

LPAD/Limited Use insights; NI margins for TB and candidiasis

Dear All,  I want to call your attention to next week’s AMDAC (Antimicrobial Drugs Advisory Committee) for rezafungin. This meeting is Tue 24 Jan 2023, 9a-4.30p ET and the meeting materials are provided here.  Rezafungin is an antifungal but please don’t let that dissuade you from attending: this AMDAC promises to be an important discussion

Notable webinars: Pediatric drug development; Drug delivery systems

Dear All, The high-value webinars below have just crossed my radar.  First up, we have a very important 2-part webinar on pediatric antibacterial drug development entitled “Improving the Investigation of New Antibacterial Agents for Use in Children: Ensuring That Our Youngest Patients Also Benefit from Innovative Treatments of Infections Caused by Multi-Drug Resistant Bacteria.” Here are the

CDC BAA: Surveillance, endpoints for decolonization, and more…

Dear All, Greetings in the new year! I just tonight picked up on this fascinating BAA (Broad Agency Announcement) from CDC: BAA 75D301-23-R-72545 as described on this general overview webpage: The BAA itself  Timeline: Initial white papers (max 4 pages, see page 76 of the BAA for details) are due by 3 Feb 2023; Invitations for

Scroll to Top